Lenalidomide

CHICAGO - In this video, Reid Merryman, MD, discusses updates on a trial testing the combination of epcoritamab, rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma.

NEW ORLEANS — A novel combination induced response among patients with pretreated multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses potentially practice-changing early research on treatments for newly diagnosed multiple myeloma presented at the ASH Annual Meeting and Exposition.

Idecabtagene vicleucel extended PFS compared with standard regimens for adults with advanced multiple myeloma, according to topline data released by the agent’s manufacturer.

A quadruplet regimen comprising the monoclonal antibody elotuzumab plus weekly carfilzomib, lenalidomide and dexamethasone conferred a 72% 3-year PFS rate among patients with newly diagnosed multiple myeloma, phase 2 trial results showed.

In this video, Paul Richardson, MD, director of clinical research at Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses the phase III DETERMINATION study in multiple myeloma presented at ASCO Annual Meeting.

CHICAGO — Lenalidomide, bortezomib and dexamethasone plus autologous stem cell transplantation and lenalidomide-based maintenance conferred a significant PFS benefit among patients with newly diagnosed multiple myeloma.

A dose-adjusted lenalidomide regimen that included discontinuation of dexamethasone after 9 months appeared safe and led to similar outcomes as continuous lenalidomide plus dexamethasone among older patients with multiple myeloma.

We have not yet moved away from bone marrow transplant for these patients, and I believe the best outcomes remain with an early transplant.

The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly diagnosed diffuse large B-cell lymphoma, according to study results published in Journal of Clinical Oncology.